ALK and non-small cell lung carcinoma: The latest NCCN guidelines [NCCN] suggest that patients with completely resected IIB-IIIA (N1) NSCLC should undergo adjuvant systemic therapy with either Osimertinib—if EGFR-mutated and after receiving standard adjuvant chemotherapy, or if ineligible to receive platinum-based chemotherapy—or Atezolizumab, if PD-L1 ≥ 1% and EGFR and ALK are both the wild type, and after receiving standard adjuvant chemotherapy (www.nccn.org/guidelines, accessed on 7 July 2024).